Form 4: Neurogene Director Granted Stock Options

Neurogene Inc. Director Rohan Palekar was granted 12,050 non-qualified stock options with an exercise price of $17.64, vesting monthly over one year.

Summary

• Rohan Palekar, a Director at Neurogene Inc. (NGNE), acquired 12,050 non-qualified stock options.
• The options have an exercise price of $17.64 per share.
• The grant date for these options was February 20, 2026.
• Vesting will occur monthly, with 1/12 of the total shares vesting each month, starting March 20, 2026.
• The options will be fully vested on February 20, 2027, contingent on Mr. Palekar's continued service to the Issuer.
• The expiration date for these stock options is February 20, 2036.
• Following this transaction, Mr. Palekar beneficially owns 12,050 derivative securities (options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, representing a routine compensation action that aligns management incentives with shareholder interests, without indicating any immediate operational or financial performance changes.

Positives

• The grant of stock options aligns the interests of Director Rohan Palekar with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from a key board member.

Future Outlook

The vesting schedule for the stock options indicates an expectation of Rohan Palekar's continued service to Neurogene Inc. through at least February 2027.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages. This method aims to align the interests of leadership with long-term shareholder value creation by tying compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of 12,050 options to a director is within the typical range for compensation packages in early-stage biotechnology companies like Neurogene Inc., which often use equity to attract and retain talent given their growth potential.
• The one-year monthly vesting schedule is a standard approach, similar to grants observed at comparable biotech firms such as CRISPR Therapeutics AG or Editas Medicine, Inc., ensuring continued engagement over a defined period.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can positively impact shareholders by aligning the director's financial incentives with the company's long-term stock performance and value creation.

Next Steps

• The options will continue to vest monthly, subject to Rohan Palekar's ongoing service to Neurogene Inc.

Key Dates

Keywords

Neurogene Inc., NGNE, Rohan Palekar, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Vesting Schedule